李曼, 杨玉婷, 何勤, 张志荣. 纳米载体在肿瘤免疫治疗中的研究进展J. 药学学报, 2017,52(12): 1839-1848. doi: 10.16438/j.0513-4870.2017-0850
引用本文: 李曼, 杨玉婷, 何勤, 张志荣. 纳米载体在肿瘤免疫治疗中的研究进展J. 药学学报, 2017,52(12): 1839-1848. doi: 10.16438/j.0513-4870.2017-0850
LI Man, YANG Yu-ting, HE Qin, ZHANG Zhi-rong. Recent advances of nanocarriers in tumor immunotherapyJ. Acta Pharmaceutica Sinica, 2017,52(12): 1839-1848. doi: 10.16438/j.0513-4870.2017-0850
Citation: LI Man, YANG Yu-ting, HE Qin, ZHANG Zhi-rong. Recent advances of nanocarriers in tumor immunotherapyJ. Acta Pharmaceutica Sinica, 2017,52(12): 1839-1848. doi: 10.16438/j.0513-4870.2017-0850

纳米载体在肿瘤免疫治疗中的研究进展

Recent advances of nanocarriers in tumor immunotherapy

  • 摘要: 近20年来,肿瘤免疫治疗已获得显著进展,众多研究以及临床试验均展现出良好的肿瘤抑制效果。免疫治疗主要从两方面体现对肿瘤的抑制作用:一是在肿瘤发生期间诱发机体产生有效的抗肿瘤免疫应答,二是通过免疫记忆实现对肿瘤的长期监控,降低肿瘤复发的可能性。通过纳米载体递送具有治疗作用的免疫调节剂是目前研究较多的一种免疫治疗策略。研究发现纳米载体具有特殊的理化性质,易于被免疫细胞吞噬,调节免疫系统反应强度,最终有效诱发机体对肿瘤的免疫级联反应,实现对肿瘤生长的抑制。本文将对近年来新型纳米载体介导的抗肿瘤免疫治疗研究进展进行总结。

     

    Abstract: In the past 20 years, tumor immunotherapy has made a significant progress in tumor inhibition effects in both laboratory studies and clinical trails. In the immune response to tumor, effective antitumor immunity is induced during the tumor progress; long-term monitoring of the tumor would be achieved through the immune memory, reducing the possibility of tumor recurrence. In the immune treatment strategies, a focus is delivery of therapeutic immune regulators with nanocarriers. It has been demonstrated that due to the special physical and chemical properties, nanocarriers are easily internalized by immune cells, which regulate the immune responses and effectively induce anti-tumor immune cascade to achieve the tumor inhibition effect. In this paper, we will discuss the progress of nanocarrier-mediated antitumor immunotherapy in recent years.

     

/

返回文章
返回